LAVA Therapeutics NV
NASDAQ:LVTX

Watchlist Manager
LAVA Therapeutics NV Logo
LAVA Therapeutics NV
NASDAQ:LVTX
Watchlist
Price: 0.9838 USD -9.74% Market Closed
Market Cap: 25.9m USD
Have any thoughts about
LAVA Therapeutics NV?
Write Note

LAVA Therapeutics NV
Total Receivables

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

LAVA Therapeutics NV
Total Receivables Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Receivables CAGR 3Y CAGR 5Y CAGR 10Y
LAVA Therapeutics NV
NASDAQ:LVTX
Total Receivables
$1.7m
CAGR 3-Years
4%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharming Group NV
AEX:PHARM
Total Receivables
$48.2m
CAGR 3-Years
20%
CAGR 5-Years
12%
CAGR 10-Years
40%
ProQR Therapeutics NV
NASDAQ:PRQR
Total Receivables
€770k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Uniqure NV
NASDAQ:QURE
Total Receivables
$5.3m
CAGR 3-Years
12%
CAGR 5-Years
121%
CAGR 10-Years
6%
argenx SE
XBRU:ARGX
Total Receivables
$655.6m
CAGR 3-Years
279%
CAGR 5-Years
159%
CAGR 10-Years
94%
Merus NV
NASDAQ:MRUS
Total Receivables
$3.9m
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
N/A
No Stocks Found

LAVA Therapeutics NV
Glance View

Market Cap
25.9m USD
Industry
Biotechnology

LAVA Therapeutics NV operates as a biotechnology company, which develops immune oncology biopharmaceutical products. The company is headquartered in Utrecht, Utrecht and currently employs 55 full-time employees. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.

LVTX Intrinsic Value
2.1828 USD
Undervaluation 55%
Intrinsic Value
Price

See Also

What is LAVA Therapeutics NV's Total Receivables?
Total Receivables
1.7m USD

Based on the financial report for Dec 31, 2023, LAVA Therapeutics NV's Total Receivables amounts to 1.7m USD.

What is LAVA Therapeutics NV's Total Receivables growth rate?
Total Receivables CAGR 3Y
4%

Over the last year, the Total Receivables growth was -49%. The average annual Total Receivables growth rates for LAVA Therapeutics NV have been 4% over the past three years .

Back to Top